Context Therapeutics Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNTX research report →
Range $4.5 – $6
Price Chart
About the company
Context Therapeutics Inc. , a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
- CEO
- Martin A. Lehr
- IPO
- 2021
- Employees
- 15
- HQ
- Philadelphia, PA, US
Get TickerSpark's AI analysis on CNTX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $47.75M
- P/E
- -1.08
- PEG
- 0.04
- P/S
- 0.00
- P/B
- 1.30
- EV/EBITDA
- -0.11
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -82.06%
- ROIC
- -126.84%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-39,702,631
- Net Income
- $-36,123,615-35.2%
- EPS
- $-0.38+17.4%
- OCF Growth
- -81.3%
- FCF Growth
- +9.9%
- 52W High
- $3.62
- 52W Low
- $0.43
- 50D MA
- $0.66
- 200D MA
- $1.68
- Beta
- 1.75
- RSI (14)
- 41
- Avg Volume
- 2.69M
No earnings-call transcripts are available for CNTX yet.
- Free Float
- 70.4%
- Shares Outstanding
- 91.88M
- Float Shares
- 64.66M
of shares held by institutions
42 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Vanguard Group Inc | 3.79M | ▲ 290.88K |
| Mill Creek Capital Advisors, LLC | 104.63K | 0 |
| Congress Wealth Management LLC / De / | 15.00K | 0 |
Held by 59 ETFs
Biggest fund positions in CNTX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jun 24, 26 | Pasternak Andy | other | 45,000 |
| Jun 24, 26 | Stacey Jennifer Evans | other | 45,000 |
| Jun 24, 26 | West Linda | other | 45,000 |
| Jun 24, 26 | Smith Karen L. | other | 45,000 |
| Jun 24, 26 | Walker Luke Nathaniel | other | 45,000 |
| Jun 24, 26 | Kantoff Philip W. | other | 45,000 |
| Feb 19, 26 | Levit Alex C. | other | 270,000 |
| Feb 19, 26 | Minai-Azary Jennifer Lynn | other | 275,000 |
| Feb 19, 26 | Chagin Karen Deborah | other | 290,000 |
| Feb 19, 26 | Lehr Martin A. | other | 815,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNTX coverage
Recent articles, reports, and earnings notes.
No research on CNTX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNTX report →Context Therapeutics Reports Second Quarter 2026 Operating and Pipeline Progress
globenewswire.com · Aug 5
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jul 10
Context Therapeutics Added to Russell 2000® and Russell 3000® Indexes
globenewswire.com · Jul 6
Small Biotech Context Therapeutics Reports 29% Response Rate In Ovarian Cancer Study
benzinga.com · Jun 15
Context Therapeutics Announces Positive Interim Efficacy and Safety Results from Ongoing Phase 1 Clinical Trial for CTIM-76
globenewswire.com · Jun 15
Context Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com · Jun 9
Context Therapeutics to Present at the Jefferies Global Healthcare Conference
globenewswire.com · May 27
Context Therapeutics Enters into License Agreement Amendment with BioAtla for CT-202
globenewswire.com · May 18
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.